



bls



Amendments to the Claims:

1. (~~Original~~ Currently Amended) A compound of formula (I),



wherein

m is 1, 2 or 3;

R¹ is methyl, chloro, bromo or fluoro;

R² is -Q¹-Q²-Q³-Q⁴ or (C₁-C₆)alkyl,

- said (C₁-C₆)alkyl is substituted with one to three OR⁴, COOR⁴, NR⁴R⁵, NRC(=O)R⁴, C(=O)NR⁴R⁵ or SO₂NR⁴R⁵;
- R⁴ is (C₁-C₆)alkyl substituted with one to three F, CN, S(=O)R⁶, SO₃H, SO₂R⁶, SR⁷, C(=O)-NH-SO₂-CH₃, C(=O)R⁷, NR'C(=O)R⁷, NR'SO₂R⁶, C(=O)NR⁷R⁸, O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸;
- R⁵ is H or (C₁-C₆)alkyl optionally substituted with one to three F, CN, S(=O)R⁶, SO₃H, SO₂R⁶, SR⁷, C(=O)-NH-SO₂-CH₃, C(=O)R⁷, NR'C(=O)R⁷, NR'SO₂R⁶, C(=O)NR⁷R⁸, O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; or
- said (C₁-C₆)alkyl is
 - 1) substituted with one to three OC(=O)R^{4a}, SR^{4a}, S(=O)R³, C(=NR⁹)R^{4a}, C(=NR⁹)-NR^{4a}R^{5a}, NR-C(=NR⁹)-NR^{4a}R^{5a}, NR-COOR^{4a}, NR-C(=O)-NR^{4a}R^{5a}, NR-SO₂-NR^{4a}R^{5a}, NR-C(=NR⁹)-R^{4a} or NR-SO₂-R³; and
 - 2) optionally substituted with one or two OR^{4a}, COOR^{4a}, C(=O)-R^{4a}, NR^{4a}R^{5a}, NRC(=O)R^{4a}, C(=O)NR^{4a}R^{5a} or SO₂NR^{4a}R^{5a};
- R⁹ is H, CN, OH, OCH₃, SO₂CH₃, SO₂NH₂ or (C₁-C₆)alkyl; and
- R³ is (C₁-C₆)alkyl optionally substituted with one to three F, CN, S(=O)R⁶, SO₃H, SO₂R⁶, C(=O)-NH-SO₂-CH₃, OR⁷, SR⁷, COOR⁷, C(=O)R⁷, O-C(=O)NR⁷R⁸, NR⁷R⁸, NR'C(=O)R⁷, NR'SO₂R⁶, C(=O)NR⁷R⁸ or SO₂NR⁷R⁸;

- R^{4a} and R^{5a} are the same or different and are H or (C_1-C_6) alkyl optionally substituted with one to three F, CN, $S(=O)R^6$, SO_3H , SO_2R^6 , $C(=O)-NH-SO_2-CH_3$, OR^7 , SR^7 , $COOR^7$, $C(=O)R^7$, $O-C(=O)NR^7R^8$, NR^7R^8 , $NR^7C(=O)R^7$, $NR^7SO_2R^6$, $C(=O)NR^7R^8$ or $SO_2NR^7R^8$;
 Q^1 is a single bond or (C_1-C_6) alkylene;
 Q^2 is a saturated 4- to 6-membered heterocyclyl comprising one or two O or N;
 Q^3 is (C_1-C_6) alkylene;
 Q^4 is a 4 to 8-membered, aromatic or non aromatic, heterocyclyl comprising 1 to 4 -O-, -S-, -S(=O)-, -SO₂- or -N-, said heterocyclyl being optionally substituted with one to three -OR, -NRR', -CN or $-(C_1-C_6)$ alkyl;
R is H or (C_1-C_6) alkyl;
 R^6 is (C_1-C_6) alkyl optionally substituted with one or two -OR';
 R^7 and R^8 are the same or different and are H or (C_1-C_6) alkyl optionally substituted with one or two -OR';
 R^9 is H, -CN, -OH, -OCH₃, -SO₂CH₃, -SO₂NH₂ or $-(C_1-C_6)$ alkyl;
R' is H or (C_1-C_6) alkyl; and
R'' is H or (C_1-C_6) alkyl;
provided that
 - 1) the atom of Q^2 bound to Q^1 is a carbon atom; and
 - 2) the atom of Q^4 bound to Q^3 is a carbon atom;
or a racemic form, isomer, pharmaceutically acceptable salts, hydrates, solvates and polymorphs derivative-thereof.

2. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6) alkyl substituted with -OR⁴, -COOR⁴, -NR⁴R⁵, NRC(=O)R⁴, -C(=O)NR⁴R⁵ or -SO₂NR⁴R⁵; R⁴ is (C_1-C_6) alkyl substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NR⁷C(=O)R⁷, -NR⁷SO₂R⁶, -C(=O)NR⁷R⁸, -O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; R⁵ is H or (C_1-C_6) alkyl optionally substituted with one to three -S(=O)R⁶, -SO₂R⁶, -NR⁷C(=O)R⁷, -NR⁷SO₂R⁶, -C(=O)NR⁷R⁸, -O-C(=O)NR⁷R⁸ or SO₂NR⁷R⁸; R⁶ is (C_1-C_6) alkyl; and R', R⁷ and R⁸ are the same or different and are H or (C_1-C_6) alkyl.

3. (Original) A compound of claim 1 wherein R^2 is (C_1-C_4) alkyl substituted with $-NR^4R^5$ or $-C(=O)NR^4R^5$; R^4 is (C_1-C_6) alkyl substituted with $-S(=O)CH_3$, $-NHC(=O)CH_3$ or $-C(=O)NR^7R^8$; R^5 is H or methyl; and R^7 and R^8 are the same or different and are H or methyl.
4. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6) alkyl substituted with one to three $-OC(=O)R^{4a}$, $-SR^{4a}$, $-S(=O)R^3$, $-NR^{4a}COOR^{4a}$, $-NR-C(=O)-NR^{4a}R^{5a}$, $-NR-SO_2-NR^{4a}R^{5a}$ or $-NR-SO_2-R^3$; and said (C_1-C_6) alkyl is optionally substituted with $-OH$ or $-OCH_3$; R is H or CH_3 ; R^3 is (C_1-C_6) alkyl optionally substituted with one to three $-F$, $-CN$, $-S(=O)R^6$, $-SO_3H$, $-SO_2R^6$, $-C(=O)-NH-SO_2-CH_3$, $-OR^7$, $-SR^7$, $-COOR^7$, $-C(=O)R^7$, $-O-C(=O)NR^7R^8$, $-NR^7R^8$, $-NR^7C(=O)R^7$, $-NR^7SO_2R^6$, $-C(=O)NR^7R^8$ or $-SO_2NR^7R^8$; R^{4a} and R^{5a} are the same or different and are H, (C_1-C_6) alkyl optionally substituted with one to three $-F$, $-CN$, $-S(=O)R^6$, $-SO_3H$, $-SO_2R^6$, $-C(=O)-NH-SO_2-CH_3$, $-OR^7$, $-SR^7$, $-COOR^7$, $-C(=O)R^7$, $-O-C(=O)NR^7R^8$, $-NR^7R^8$, $-NR^7C(=O)R^7$, $-NR^7SO_2R^6$, $-C(=O)NR^7R^8$ or $-SO_2NR^7R^8$; R^6 is (C_1-C_6) alkyl; and R^7 , R^7 and R^8 are the same or different and are H or (C_1-C_6) alkyl.
5. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6) alkyl substituted with $-S(=O)R^3$; R^3 is (C_1-C_6) alkyl optionally substituted with one to three $-S(=O)R^6$, $-SO_2R^6$, $-NR^7R^8$, $-OR^7$, $-NR^7C(=O)R^7$, $-NR^7SO_2R^6$; $-C(=O)NR^7R^8$; or $-O-C(=O)NR^7R^8$; R^6 is (C_1-C_6) alkyl; and R^7 , R^7 and R^8 are the same or different and are H or (C_1-C_6) alkyl.
6. (Original) A compound of claim 1 wherein R^2 is (C_1-C_6) alkyl substituted with $-S(=O)R^3$; and R^3 is (C_1-C_6) alkyl, preferably methyl.
7. (Original) A compound of claim 1 wherein R^2 is $Q^1-Q^2-Q^3-Q^4$; Q^2 is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom; Q^3 is a linear (C_1-C_4) alkylene group; Q^4 is a 5- or 6-membered aromatic heterocycle comprising one to four nitrogen atoms, said heterocycle being optionally substituted with methyl.

8. (Original) A compound of claim 1 wherein R^2 is $Q^1-Q^2-Q^3-Q^4$; Q^1 is a single bond; Q^2 is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom; Q^3 is $-CH_2-$; and Q^4 is a 5-membered, aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl.
9. (Original) A compound of claim 8 wherein R^1 is $-Cl$ or $-F$.
10. (Original) A compound of claim 8 wherein m is 2.
11. (Original~~Currently Amended~~) A compound according to claim 8 and selected from
5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
8'-chloro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
5'-(2-{[2-(acetylamino)ethyl]amino}ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;
8'-fluoro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; or
8'-fluoro-5'-(2-{[1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy})1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.
12. (Original~~Canceled~~) ~~A method of treating a disease for which PDE7 inhibition therapy is indicated in a mammal comprising administering to said mammal in need thereof a compound of claim 1.~~
13. (Original~~Currently Amended~~) A method of claim 12 wherein said treating a disease is selected from T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, leukemia, acquired immune deficiency syndrome (AIDS),

~~allergy, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, pancreatitis, dermatoses, psoriasis, atopic dermatitis, glomerulonephritis, conjunctivitis, autoimmune diabete, graft rejection, epilepsy, muscular atrophy and systemic lupus erythematosus~~ in a mammal comprising administering to said mammal in need thereof, a compound of claim 1.

14. (Original) A method of claim 13 wherein said disease is asthma, allergy or atopic dermatitis.
15. (Original) A method of claim 13 wherein said disease is osteoporosis.
16. (Original) A method of claim 13 wherein said disease is cancer.
17. (Original) A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.